Axcelis Technologies, Inc. filed a Form 8-K on November 2, 2026, disclosing that the expected closing of its planned merger with Veeco Instruments Inc. has been extended to by the end of the first quarter of 2027, pending outstanding regulatory approvals.

Key Highlights

  • Revised timeline: Axcelis now expects the merger with Veeco to close by the end of Q1 2027, subject to satisfaction or waiver of all closing conditions.
  • Original merger agreement: The Agreement and Plan of Merger was signed on September 30, 2025, under which Veeco would survive as a wholly owned subsidiary of Axcelis.
  • China regulatory clearance pending: The filing identifies approval from China's State Administration for Market Regulation (SAMR) as an outstanding closing condition.
  • New HSR Act submission required: The parties plan to make a new submission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 due to expiry of the current clearance, adding a waiting-period condition to closing.
  • Registration statement effective: The Form S-4 registration statement, originally filed December 8, 2025 and amended December 29, 2025, was declared effective by the SEC on December 31, 2025.
  • Joint proxy statement mailed: A definitive joint proxy statement/prospectus was filed and mailing to stockholders commenced on or about December 31, 2025.

Axcelis Merger Closing Delayed as SAMR Clearance and HSR Refiling Remain Outstanding

Axcelis Technologies, a Beverly, Massachusetts-based maker of ion implant systems used in semiconductor wafer fabrication, disclosed in the November 2, 2026 filing that it now expects to complete its acquisition of Veeco Instruments by the end of the first quarter of 2027. The company noted, according to the filing, that "there can be no assurances that the closing will occur on this timeline." The merger, structured so that Veeco survives as a wholly owned subsidiary of Axcelis, was originally agreed upon September 30, 2025.

The filing identifies two regulatory hurdles delaying the close. First, clearance from SAMR - the Chinese antitrust authority - remains outstanding, and the parties reported they "continue to work constructively with SAMR to obtain clearance." Second, the current clearance obtained under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 is pending expiry, requiring the parties to file a new HSR submission promptly. Closing is conditioned on the expiration or early termination of the waiting period for that new submission.

The filing was made under Rule 425 of the Securities Act and simultaneously satisfies obligations under the Securities Exchange Act. Axcelis noted that statements regarding the expected closing timeline and potential transaction benefits are forward-looking and subject to risks enumerated in the filing, including failure to obtain regulatory approvals on a timely basis, failure to satisfy other closing conditions, and risks that the businesses may not be integrated successfully or that expected benefits may take longer to realize than anticipated. Those characterizations are the company's own, subject to its cautionary language.

What Was Disclosed

Axcelis Technologies filed an 8-K on November 2, 2026, disclosing that its planned merger with Veeco Instruments is now expected to close by end of Q1 2027. Two regulatory items remain open: SAMR approval in China and a new HSR Act filing following expiry of the prior clearance.